TBPH - Earnings call 3 2023 | Theravance Biopharma, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma Third Quarter 2023 Conference Call. [Operator Instructions] Also, today's conference call is being recorded. And now I would like to turn the call over to Rick Winningham, Chief Executive Officer. Please go ahead, sir.

Rick Winningham

Good afternoon, everyone, and thank you for joining the Theravance Biopharma Third Quarter 2023 Earnings Results Conference Call.

X. Slide to Turning clinical that and will our uncertainties, of timing expected you financial and that results. development forward-looking involve benefits of anticipated products, risks including our regulatory this remind filings contain expected call statements pipeline, trials, I'd statements about that Development; results by X, Slide and concerning of Farnum, statements joined materially today forward-looking Graham, Business Aziz to I'm from our Officer; Research SEC. On factors Financial Sawaf, Information described with further the differ Theravance's Chief our our Rick Head is Officer. Rhonda in could cause our filings and again Chief

share quarter the patients results efficacy. top share and findings with data to to We severe Moving initiating highest organization, with the our to company, these make previous of in of on market exciting namely: to consistent our of channel line completed the advancing CYPRESS in III include continued III half just objectives. Beginning of retail enrollment of and representing of since learned third hospital-based and moderate the our total advancing data million we've we've the continue several growth the YUPELRI's that very development, combined Chinese Phase third quarter study YUPELRI grow communicated results while performance, X% completing our third and in achieving Phase year, good growth positive study Slide progress were we net during X. quarter on net and the that, non-GAAP second Throughout profitability strong to gains. continued new to quarterly disclosing sales, was study; another for study; YUPELRI, expect strategic achieved team a sales Viatris' YUPELRI further and continue COPD subject -- that and commercial Highlights in growth. PIFR-X PIFR-X $XX.X objectives year-on-year Based January. In launch. the year, against our progress with the outstanding performance YUPELRI's and in to the

Viatris in China in move at with partners a plan forward Our to mid-XXXX. registrational filing

morbidity stands milestones As a over Theravance with royalties development a reminder, mortality to and cause and XXX expanded is China in well our with receive on individuals agreement million as affected, low XXXX and sales and leading territories China in as sales adjacent Viatris. double-digit under COPD of

and Moving to CYPRESS. ampreloxetine

additional month continue Disorders and International to the globally Disease in We at the sites Parkinson's Congress and X quarter, open in American we abstracts Movement and the Autonomic Rico. this during data on later will present Society August, presented we at Puerto

X.X time the need we through our fourth no moment bringing to Theravance future; when of growing us a program the line a putting a coming non-GAAP of how organization on capital source in to with the and rare streamlined roughly of of key was assets. flows realize the In the driven Slide have a has we a approximately from see financials. today. value like years assets: us in ampreloxetine, since capital top of We Theravance unique potential capital we biotech access on become effective $XX to and final bright to take total management. to believe set X been $XX Next, YUPELRI, achieving at focused markets full asset neurological a to profile cash challenging. during by a data. Theravance $XXX,XXX of the objective a in these maximizing the is YUPELRI currently the debt-free We non-GAAP profitability. a quarter, close markets and another expense million with of short, embody returns combination returned reported million to inception I'd growth This level loss $XXX a our a position X, return quarter. On million

As company continue shareholder and debt, of the sale that the business, following Board we opportunities the and enhancements all review of pay value. to the return strategy expense to the substantial comprehensively of streamlining and down interest, program, undertook Board management elements complete capital our the of TRELEGY royalty maximize

Now from Graham I rare is XX,XXX in with turning the will potential We've XX,XXX which States, addressable XX,XXX MSA, cover people to approximately disorder ampreloxetine's of Slide beginning United past, Rick X. affecting the symptomatic MSA the in nOH. population. to in patient suffer a and discussed neurological

can is of substantial in we lives its on own, a ampreloxetine exploring from since also their profound can and and opportunity which to limited given nOH patients hope of we're represents treatment quality the this suffering as as have ways the the many life While possible available. currently their improve options caregivers globally our condition MSA make available on patients impact this of

if If one China. estimated you patients includes have and increases MSA turn Japan you see the can X, to of Europe, to by factor of Slide that of number roughly a X, symptoms nOH

Theravance remains exploring worldwide, for in are that ways committed XXXX to need X, that well. On the to U.S. to rights global I'd the U.S. granted patients ampreloxetine, the to outside retains extending patients note reach Given Slide we as IP

In orphan received year. earlier we drug addition, designation this

product you well from user As many designation of of years confers market drug as orphan exclusivity a fees. X as know, to exemption

their high made excluded with commercial particularly The price also Drugs for mandates as that Medicare orphan Inflation such important and reductions molecules. are ampreloxetine their X comes for after this negotiate a which requirement, availability when with drugs single certain pricing. years designation small it's Reduction spending the from value to development. it protects However, in Act investments of supports

to the today. like Head company taking as announced be will turn with Áine Miller the we Development. over over Rick leadership Graham, R&D leaving I'd transition Rick in the Before of address I call to

development some the with and a study transition he'll of -- an her is filing approval has months strategic and on take CYPRESS' an ready its organization, and staying ideal established beyond. on and Áine leadership, will to CYPRESS built Development. With Although the call the many PIFR-X and be exceptional his to underway, record been approach time success, to Áine I'll to ampreloxetine's make now CYPRESS capabilities regulatory we're for tenure some have Rick several thrilled for for clinical study, Rick? exceptional of conclusion, to key turn completion Rick she role the begin comments of this be With ampreloxetine. proven and to ensure at this time, guide as the its the we that, organization track an Theravance well successful over Head relies potential transition. Over additional on Theravance, of through

Richard Graham

Thanks, Rick.

as patients additional filing and by we me on as Let X detail in with unmet we the quickly believe well move why and approval. ampreloxetine Slide nOH some toward providing successfully need can on MSA begin for NDA

standing important and progression to can a and, are effective significant to symptomatic it's MSA persistent of deconditioning that time. have impact sitting without combined upon life symptoms nOH lasting First, or treatment, disease on over have of effects. quality nOH Moreover, lead recognize that effects the

on a demonstrated in study, the preexisting signal the profile use, there the symptoms and study, was Phase especially supine broad to will ampreloxetine volunteers hypertension, compelling is we healthy is As as that Phase effects therapeutic despite If date. In Study a therapies life than own value well using highlight for replicated here, amongst clinically supine which the impact carry studies blood no in caregivers. is patients OHSA symptoms X norepinephrine, patient's hypotension treatment in the in to negative XXXX ongoing an impacting many no III and warnings studied approved score. hypertension quality which CYPRESS efficacy patients and on highlight available differently III and this MSA safety interventions. side XXX important the by consistent Currently pressure on believe orthostatic the availability placebo XXXX substantial why have works as patients' patients relevant their effects a to the hypertension impact therapies and a nOH cardinal disease. Ampreloxetine we evaluating consistently of and to effect resulting over evaluated supine supine treat for effect of we patients compared of from in MSA use nOH ampreloxetine believe safety bring composite of durable

past, well peripheral in more why prior neurogenic symptoms, an So Study and nOH sitting their trials. What's administration XXXX. in in showed pressure of sense to with of as standing norepinephrine works blood clinical often X mechanism leads the that levels action treatment of quality ampreloxetine Ampreloxetine symptoms let's XX. particular increase and upon on we impact Slide Patients described persistent shown raise MSA patients which life. of standing, blood talk with particularly address nerves pressure their approximate systolic or which debilitating decreases impact patients. the CYPRESS experience In OH in independence on intact after our the is importance to have MSA of about suited endogenous in it's X.X-fold ampreloxetine's of on to weeks

after inhibitor, As increased a thereby where impacting to pressure on blood XX able of the withdrawal of in prevent by impact norepinephrine reduced period symptoms state. decrease blood marked minutes the blood entering weeks ampreloxetine XXXX, potential to the pressure reuptake the blood standing. has vascular during and Study pressure in on restores ampreloxetine remaining increasing resting in pressure was X those endogenous treatment tone patients After a therapy, decrease placebo with randomized norepinephrine, saw

as which on Finally, X.X receiving improvement an placebo to ampreloxetine in composite experienced as symptom well same was of clinically significant. statistically score, patients significant study, nominally relative the points OHSA the

Taken rare studies believe technical in lands the CYPRESS' together, conducted at neurological of recent we diseases potential upper and success of the years. for range end in

outlook. the Moving of I'll to regulatory recap the bottom briefly ampreloxetine's slide,

of MSA, with as reminder, with patients. The company discuss Study proposal Type completion composite a C CYPRESS. with results pure a primary to prespecified As both analysis FDA the Parkinson's study the the of FDA XXXX, autonomic Phase included use and the our Upon XXXX OHSA meeting to XXXX patients held disease Study score III failure. the interpretation the of the and endpoint MSA for agreed

XXXX FDA one approval is the successful nOH given This the seriousness of substantial of In full the agreed for required and MSA, standard well-controlled the we addition, that meet evidence trial. with additional could CYPRESS. in results

substantial it's we potential successful. could the and we file to expedited. line Finally, from completed to important necessary NDA an filing that already the ampreloxetine approval CYPRESS top we work disclosure be believe Thus, for be time of to understand that body should have believe

for support from appointment. I'll a say Áine the the through with the company we my XXXX to PIFR-X for you to to I'm with turn and thrilled and I'm genuinely departure readout Áine. Thank about Before to stakeholders transition and path the company. in to external committed support I'd on a our Áine the with Head colleagues have to and line the and including new ensuring optimistic early I'm friends Winningham of results and and words I've company. CYPRESS Biopharma. several years to deliverables, Development, X it to about mentorship, confidence her current Rick Miller, accountability trust top seamless the upcoming capitalizing your ahead the for momentum transitioning Theravance continue I then past future the the over and while few with fully of his worked like over Rhonda, the the of success

So to now over I'll turn the Rhonda YUPELRI. discuss call to

Rhonda Farnum

Thanks, Rick.

on Slide snapshot begin value of a with Theravance. XX Let's to YUPELRI's

of in in I'll last detail moment, enjoyed quarter to its growth bringing sales greater XX-month As YUPELRI a $XXX million. cover another approximately successful

through we Theravance Viatris. XX% of profits entitled always our As to collaboration note, with is YUPELRI's

direct the value Viatris. achieve and a COPD. value China and registration-enabling relationship function profits where make therapy source advantages in shortly, this addition also study. additional of just of milestones is the In territories we LAMA stand for YUPELRI as to our details One to successful YUPELRI's to III of and adjacent through we with of demonstrated which important U.S., through maintenance plan the in available lung completed royalties YUPELRI study, potential benefits for the strong This treatment foundational Viatris Phase contribution

for in territories. basis results, up million associated China YUPELRI in our at We receive to double-digit mid-XXXX. sales in tiered file monotherapy partners royalties plan the these stand On to on with low payments milestone these to as Viatris well $XX of in approval as

Slide to Turning XX.

consistent coordination that believe We a educating strategic a level million. result of and support, net XXXX X% use in total achieved the see year-on-year for of settings. quarters. to which the with can up previous launch, $XX.X sales our important cover the transition performance XX, was with continuation highest quarter and net Theravance's initiatives, including remains YUPELRI of of quarter-on-quarter impacting sales see community implied is LABA, concomitant and growing performance and to key both YUPELRI care since on sales of generation fulfillment this strong XX% demand our hospital indicators relative Slide hospital This represents internally. On share benefit which YUPELRI's of third $XX.X performance, You sales million. direct I'll we from during X% the of

of a a to to require higher to for may growing or Many caregivers hospital persistency acute accounting strategic has hospital we with catalyst trip of enough a generate at consider subsequent an to the a ability the despite percentage switching care on YUPELRI point impact time the a setting total as meaningful note, hospital, business. part community of COPD the adding continue prescribing the experience in which As the YUPELRI respiratory serious for patients is use our treatment episode setting. in and regimen. Thus, of demand YUPELRI community to smaller

year-over-year. quarterly graph, of right-hand see side YUPELRI the can volume launch represents increased doses since XX% of the you on sold hospital the As QX units highest sold and

to Turning XX. Slide

YUPELRI's of long-acting to XX.X% X performance our that overall. in we overall see market. points can neb translated improved Year-over-year, share improvement nearly into hospital-based another the percentage You hospital

and our with prescription have discharge we both the achieved adoption. These receiving higher of Consistent the quarter we the interchange transition past, accounts YUPELRI in have supporting care number this the we've of success are a implemented progress programs. our implementation team's YUPELRI neb of all initiatives continue well in and a foundation are those YUPELRI terms we therapeutic the metric placed that where formulary patients the in during setting. in received as as these quarters, in of indicated protocol in reflects As have majority the share to market strategy, making on of hospital the past community hospitals at successfully

Turning to development in market share community setting. the our

performance point of of and over overall same efforts story. long-acting this high side another YUPELRI much percentage slide, right-hand XX.X%, At which market an share of sequentially. Picking on Viatris up X channel, retail represents the XX. XX% it in of On The the an community is the Theravance solid the on performance and quarterly neb all-time improvement combined approximately drove volume. Slide represented

of As growth retail depicted sequentially side year-on-year. to left-hand slightly prescription on X% at slide, total the the XX% accelerated and

our larger our metric lags but adjudication accounts overall DME ability remain to volume, medical retail the demand or at for durable to Medicare trends, Part fulfillment portion filled best trends reporting to quarter prescriptions a total of due process. still While real-time community community gauge behind equipment in a B report

time factors, given a of to performance net activity in we've may not including from retail alone which to be inventory, such, As indicative due sales time. any quarter number of experienced

Turning X% product Volumes to our the new year-on-year. on XX% performance to side. right-hand declined quarter-on-quarter but grew

see performance continued doctors' office our to and as modifications. hospital with expect success results introduced continued tends commercial sales strong exacerbation of While figure recently due overall on visits exhibit significantly to fourth -- more to respiratory potential the as and initiatives well internal in correlates YUPELRI factors this quarter. in only the other seasonal turn such seen frequency, therapy trends with fluctuate the therapy seasonality, the market, as as we we Based modest in would indicators, particular as which

overall study. agents remain long-acting who the to PIFR-X well use the for brand and being maintenance the growth going as population LAMA XXXX being We treatment be remain about considered with those a uncontrolled messaging, opportunities opportunities therapy focus concomitant market. Also, short-acting patients to potential inappropriately excited as for from patients of YUPELRI report our within our GOLD as as using sizable benefit YUPELRI, YUPELRI the latter beyond. of the nebulized therapy COPD into switch The add-on handheld-only provides or there including patient in could foundational, a existing recommendation addition continued also regimens, of therapies remains population who maintenance on

of top that we line results in that We Aziz? presentation Aziz in the and to study hopeful PIFR-X positive turn the growth here the are will I January, project product we continue open the share further to a will the will financials. result that, opportunities the to review for over U.S. With

Aziz Sawaf

transformation by to today's how disciplined financial in performance. allocation Thanks, discussing driving Rhonda. to start like XX, are Beginning on our years and recent I'd capital Slide approach

XXXX. First, sales environment, COVID year net we've contribute since growth able even to YUPELRI's each through challenging been a to

our XXXX to operating XX% in reduce significant we've headcount, achieved expenses, costs. in By going action $XXX compensation, million and to a projected Second, reducing a including taken reduction in million XXXX. $XXX we've share-based focusing from portfolio

our company proceeds to eliminated $X.X the sheet we return using billion, XX%. By inflection a X a XXXX, its monetized reduced capital to share growing TRELEGY by complete, In YUPELRI capital debt. allocation these now share count a value via Third, approximately significant of strategies, for has the $XXX been balance debt-free and initiate, progressing towards million our to interest we've shareholders initiatives: achieve point. and on largely buybacks, able which focus ampreloxetine high-value and to implementing program our

to collaboration side. I'll $XX.X Turning financial XX and cover representing million the XX. through results, reported on expectations Viatris an better our recognized the revenue, XX expense quarter. in on the which all-time highlights high. partnership, cover than detailed Slides Slide our came with we Starting

disciplined GAAP main of outflow for to of quarter, distinction of loss the we noncash million and is initiative shortly research after QX, We and driver the of we late dedicated $X.X to in the compensation. that expenses largest from our cash GAAP reported assessing G&A introduced the cost-cutting metric important expense GAAP non-GAAP initiative decrease loss spend approach aimed between in a additional an million. to QX It's streamlining excluding This and remain $X and share elimination reduction initiatives management. In burn, a expenses, million in maintaining to $X.X a organization. was a with share-based the G&A within behind G&A buybacks, led incorporates at QX. non-GAAP to the cash overall Regarding note

as results can non-GAAP takes will overall and a the GAAP which forward, gain both we metric, used flow, share-based that understanding which better proxy of for into account profitability, and our investors begin can GAAP cash be Going compensation. a highlighting non-GAAP so both

worth in quarter, and with the million approximately equivalents. back $XX the and During we cash shares bought period of million $XXX ended

$XX leaving expect approximately us remaining with These reduced million to X.X on our period, repurchases as approximately have We the million count of by end. of which share return we our complete XX outstanding quarter by program, capital year-end. million shares during

Moving guidance. comment our on where to financial XX, Slide I'll

relative due share-based QX, study. R&D CYPRESS the $XX guidance In million. site to comp, tracking towards enrollment a currently for expenses, and QX expenses end in the actuals excluding increase of For of are million projected $XX R&D to slight expect lower initiation we to higher we

excluding comp, towards $XX million compared guidance are share-based our expenses QX expenses, $XX end flat SG&A relatively trending For We upper range we QX. to to of anticipate the million. of SG&A to be when

led of in As previous discussed of key this the our to of allocated change overhead. section one eliminate our is earnings R&D a a change allocated operating to the result influencing is of which lower trends our This higher has in the of allocated overhead the and call, to research decision a Q&A expense SG&A. proportion factors year, earlier proportion to proportion

For midpoint $XX the we are excluding below total now of of comp, trending million. share-based expenses, guidance

of an net million delivered another benefit on Slide TRELEGY. quarterly to reaching GSK expect a would and XX, driven for earn milestone and filing million quarter an will the now which QX, when our in net net we be billion to our for attain XX% million income ago. To first are year-to-date higher expectation XXXX that to million to milestones and year, QX income on beyond same provide believe payments the milestone in $X.X sales to primarily the we billion of conclude, as billion. return of the due potential expected positioned growth, And Nonetheless, XX% up GAAP milestone update $X.X results, of period set sales $XXX which perspective, again from in achieve $XX TRELEGY on is on and by year-to-date at in year continued we strong the expect on sales results by driven also need increased XXXX $X.X in U.S. to the XXXX with believe tax compared XXXX, from global growth sales sales non-GAAP the billion, based a QX We reach $XX loss tax $X and improve respectively, profitability at unlikely. I'll generate achieved milestone $XX to with and $X have the demonstrated well the YUPELRI. October. To million net our increased federal is first we

in a cumulative. not starting XXXX the reminder, milestones are As

milestones the would receive For achieved Rick we only to million. With million, be both remarks. call XXXX, of $XX to a back $XX for closing not Rick? turn in total I'll that,

Rick Winningham

Thanks, Aziz. context I'll by summarizing XX, the began. in finish how we On intentions of our Slide

expenses of We of conclusion many to as related work We'll as continue initiatives to patients a have continuing with future. business the on our hard should to XXXX, YUPELRI of efficiently operating advantage maximize results support the by a approach ensuring possible we eye bring positive highest royalties priorities growth and to and outcome. Simultaneously, ampreloxetine our achieving full As a approvals. as in the look should end taking the the we and forward value are possible. do while to to this access successful sharp we'll to keeping YUPELRI PIFR-X TRELEGY achieve as managing both by regulatory milestones and CYPRESS

shareholders. turn time, questions. your value to committed thank As now I'll drive your forward operator the And you I path the always, for the we attention. best remain back over for to to our for call

Operator

first David Risinger question [Operator Instructions] with from Partners. Leerink Our comes

David Risinger

Congrats questions, on have updates. the X please. I

economic patient after of CYPRESS and into when we please second in of opportunities ampreloxetine the separately, results? study, timing? should remind you study half regarding And could on 'XX could open-label the the expect enroll line last some ex YUPELRI then First, the about you the potential more process you top provide detail U.S. portion efficacy us the and

Rick Winningham

Rick, of the kind David withdrawal? randomized verbally to want open just you Sure, for outline and Dave. do label

Richard Graham

it. the Thanks for question, Yes, happy David. to do

in withdrawal a to small reminder, get after remain CYPRESS, and design happens is a open label X-week duration or to of that label placebo, is as to the the the similar study withdrawal for open design either question, an duration period. differences So what ampreloxetine randomized some is the go XXXX But patients on your period. and randomized answer with open-label for randomized study that to

So get they a data that top once cleaning on working working will X and then start weeks, line we result. through the toward

mind, Rick his in today. sites. But the add in opening in years as is we're keep process, line we said Now our remarks, approximately early study and to we're conduct still from top data estimate continue X.X

Rick Winningham

Dave, I on question next think your was economics? YUPELRI

David Risinger

Yes, ex U.S.

was... So there

Rick Winningham

Yes, ex U.S. economics.

Aziz Sawaf

Yes, take This that is Aziz. I can one, David.

the first So ex yes, to are the and file year. sales. going the components $XX.X which, there's for next the X of in U.S. economics, up The Viatris of opportunity China the were milestones that since we development just and highlighted economics application fact million to

monotherapy. million, $XX.X the $XX that to is of million Now related

is the when out to the So million break don't a our of related approval XX-Q a days, and we $X.X will now. Of be $XX is approval in and this we million, relate file rest currently. of regulatory milestones, million sales $XX $XX.X million milestone, right the of that play the outlined in an in which couple to --

opportunity, the next product. a of getting we're tiered smaller be China, in be going would in and bit milestones, to to we royalties So if the low already opportunity which China milestone double-digit China authorities probably mid-teen million addition have think $X.X I actually approve sales of And the is then low the double-digit regulatory China. Outside development a for to the royalties.

pretty focus modeling immaterial. last a the we would each bit of year, a have -- they're of most one I the recognized tiny but on have We China little much had opportunity. QX quarter, we

Operator

from with Wainwright. comes Douglas question next H.C. Our Tsao

Douglas Tsao

YUPELRI. if terms looks at the new like So the of it starting saw look to just share was hospital of it flat high XX.X%. at first We sort this maybe doses, quarter But in sort in your a sales of on relatively I hospital of terms market quarter.

basis So the those XXX you first some I maybe because you're if of just versus at share dynamics points. look quarter, help up the can understand us like

nice So there. some really performance

So in market? just overall what's on going the

Rick Winningham

the QX? do you want Rhonda, and to QX describe then

Rhonda Farnum

Yes.

to this the of quarter year. But the seeing that the beginning within pleased that to growth of certainly year, very at of build quarters adoption built has acceptance quarter certainly the and a for business. able that well had QX continue share hospital It's even to bit was to of off successful returned hospital contributed the as admissions associated experience recall, this systems being doctor we and of as So grow, approvals, as continued we in individual -- the see I performance that definitely the appointments exacerbations, market as the as situation well kind protocols what reduction with accounts half as and that look Certainly, short-acting in typically what a typically Doug, lower of team in challenges formulary lower for the the QX accomplish. in with in you think to both opportunity well the seasonally, at has and I'm is X is reduction as year some shortages reflected at these been each over high the patients. first

team. ongoing to business So for that's this the contribute to build continuing hospital the across

to the XX.X% that's contributing So market share.

Douglas Tsao

have when really necessarily as slight follow-up, at retail saw that's much decline We side, terms X%. Rx. see new nice on. We you Okay. And at a we as and what in not growth I did focus of know the a quarter-on-quarter to the look product

So or that just some context help trend. around put us understand

Rhonda Farnum

Yes.

received have in refill quarter. or patients is occur to the the already that continuing been So prescribed had for certainly prior those

product, that indicator typically to to So most looking the to or is new which with think respiratory that be seeing the I appreciate products. the But growth. at metric build, you for already associated lesser continuing TRx

As I mentioned earlier, the QX quarter. is respiratory lower typically for

Douglas Tsao

originating hospitalization the a from of Rhonda, And scripts still? retail Okay. most are

Rhonda Farnum

-- which in for with those to are We to shorter leaving the per during exposed that And in X.X still script around majority stay. in exiting, maintenance hand the see It YUPELRI I'll averages a a inpatient is prescribed persistency. majority remind patients or setting. of are be patients days you stay, a their care outpatient

Operator

next [Operator Cowen. TD Eva from Instructions] Our Privitera comes with question

Eva Xia Privitera

segment how DME talk in Can the about the partners have question larger a And growth I the portion? that segment? great YUPELRI's on about your versus you Congrats retail you and YUPELRI. about in thinking growth are since it's maybe quarter. trends

Rick Winningham

go ahead. Yes. Rhonda, yes,

Rhonda Farnum

Yes.

So as the with approximately to are being reflected scripts, the that a B Medicare have particular in DME. the time due and for real It's view not Part we challenge call, lags process quarter. adjudication associated with the

performance best contrast QX the for reflect its to on you totality in can performance. I in is So

in X% X% the DME which QX. I'll in reported So grew retail space to space, what contrast that was approximately we and the QX, for

other possible are possible that the progress to patients have that moving latest the choose fulfillment don't filled equating as being whether I of unfortunately, quickly go, gets offer that for channel as to DME that, than and or view where regardless continue retail. best that of supported ensure they through level focus to the highest So and conventional we and DME that's ensure is support to to

Eva Xia Privitera

the And a PIFR-X trial. on follow-up question

uptake? that on already the Assuming are publication of gating patients the label, would is trial successful the publication? since for what driving And would data to these be time be line potential

Rhonda Farnum

Rick. can that, I take

Rick Winningham

Yes. Go ahead.

Rhonda Farnum

peer-reviewed then team the the given standard to those is on and we peer-reviewed in to educate on individual the as I can't will so are published time with expeditiously as data. important, ability journal speak And guiding vastly associated that you've specifically. we lines one So possible move head-on. the will ensure have variability hit Publication to really highest factor the journals,

Operator

please turn Winningham now to have like go we on further sir. -- appears no the for back to ahead, conference phone. questions the It Mr. I'd

Rick Winningham

the joining in to the we we look with today. into pleased Yes. and forward really everyone made I'd growth resources the ampreloxetine. of that this behind drivers progress quarter We Thank company, the for like X and as quarter. that We're progress to YUPELRI continuing us fourth align you very much. XXXX thank

very and a day. great So for have thank much joining you us,

Operator

call. your you. thank We conference today's This Thank concludes for you participation.

You now disconnect. may

Theravance Biopharma (TBPH) 7 Nov 232023 Q3 Earnings call transcript